Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II sacituzumab govitecan in metastatic esophagogastric adenocarcinoma
2023-505257-40-00Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in gastroesophageal junction adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Overall response rate. Started Apr 2024; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-505257-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505257-40-00.